Rapport Therapeutics [RAPP] vs Regeneron [REGN] Detailed Stock Comparison

Rapport Therapeutics Inc.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Rapport Therapeutics Inc. wins in 3 metrics, Regeneron Pharmaceuticals, Inc. wins in 11 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Rapport Therapeutics Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) 21.21 18.00 Regeneron Pharmaceuticals, Inc.
Price-to-Book Ratio 3.63 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 2.37 9.51 Rapport Therapeutics Inc.
PEG Ratio 0.81 -4.80 Rapport Therapeutics Inc.
EV/EBITDA -10.31 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) 0.00% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) 0.00% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity -28.22% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -18.90% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-88.09M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 377.63% 25.39% Rapport Therapeutics Inc.
Price-to-Sales Ratio (TTM) N/A 5.50 N/A
Enterprise Value $1.28B $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio N/A 4.95 N/A
Gross Profit Margin (TTM) N/A 84.95% N/A
Revenue per Share (TTM) N/A $137 N/A
Earnings per Share (Diluted) $-2.86 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) N/A 0.40 N/A
Short % of Float 14.62% 2.55% Regeneron Pharmaceuticals, Inc.

Rapport Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

RAPP
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Rapport Therapeutics Inc.1.32%-5.06%5.52%27.78%30.63%33.37%
Regeneron Pharmaceuticals, Inc.1.58%1.16%-11.35%-20.16%-13.01%-19.01%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Rapport Therapeutics Inc.377.63%89.90%89.90%89.90%89.90%89.90%
Regeneron Pharmaceuticals, Inc.25.39%-16.92%20.10%53.41%959.24%4,557.42%

Performance & Financial Health Analysis: Rapport Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricRAPPREGN
Market Information
Market Cap i$1.74B$80.98B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i425,541642,495
90 Day Avg. Volume i343,577617,765
Last Close$37.49$628.73
52 Week Range$10.51 - $42.27$476.49 - $821.11
% from 52W High-11.31%-23.43%
All-Time High$42.27 (Sep 08, 2025)$1,211.20 (Aug 26, 2024)
% from All-Time High-11.31%-48.09%
Growth Metrics
Quarterly Revenue GrowthN/A0.03%
Quarterly Earnings GrowthN/A-0.08%
Financial Health
Profit Margin (TTM) i0.00%0.31%
Operating Margin (TTM) i0.00%0.23%
Return on Equity (TTM) i-0.28%0.15%
Debt to Equity (MRQ) i2.379.51
Cash & Liquidity
Book Value per Share (MRQ)$10.15$304.65
Cash per Share (MRQ)$10.26$83.86
Operating Cash Flow (TTM) i$-87,473,000$4.98B
Levered Free Cash Flow (TTM) i$-54,166,876$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Rapport Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricRAPP (Apr 24, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i21.2118.00
Forward P/E i-8.7614.21
PEG Ratio i0.81-4.80
Price to Sales (TTM) iN/A5.50
Price to Book (MRQ) i3.632.45
Market Capitalization
Market Capitalization i$1.74B$80.98B
Enterprise Value i$1.28B$70.98B
Enterprise Value Metrics
Enterprise to Revenue iN/A4.95
Enterprise to EBITDA i-10.3116.72
Risk & Other Metrics
Beta iN/A0.40
Book Value per Share (MRQ) i$10.15$304.65

Financial Statements Comparison: Rapport Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricRAPP (2025)REGN (2025)
Revenue/Sales i014.34B
Cost of Goods Sold iN/A2.10B
COGS % of Revenue i-14.6%
Gross Profit iN/A12.24B
Gross Margin i-85.4%
Research & Development i94.79M5.85B
Operating Income (EBIT) i-125.10M3.70B
Operating Margin i-25.8%
EBITDA i-124.08M5.00B
EBITDA Margin i-34.8%
Pre-Tax Income i-111.48M5.23B
Pre-Tax Income % of Revenue i-36.5%
Income Tax iN/A725.80M
Income Tax % of Revenue i-5.1%
Net Income (Profit) i-111.48M4.50B
Profit Margin i-31.4%

Balance Sheet & Liquidity Metrics

MetricRAPP (2025)REGN (2025)
Cash & Equivalents i52.65M3.12B
Total Current Assets i498.56M18.02B
Total Current Assets % of Revenue i-125.7%
Total Current Liabilities i19.05M4.37B
Total Current Liabilities % of Revenue i-30.5%
Long-Term Debt i8.73M2.71B
Long-Term Debt % of Revenue i-18.9%
Total Shareholders Equity i484.65M31.26B
Retained Earnings i-235.23M35.80B
Retained Earnings % of Revenue i-249.6%
Property, Plant & Equipment i14.33M1.54B

Cash Flow Statement Comparison

MetricRAPP (2025)REGN (2025)
Operating Cash Flow i-88.65M6.30B
Operating Cash Flow % of Revenue i-43.9%
Capital Expenditures i-616,0000
Free Cash Flow i-88.09M3.77B
FCF Margin i-26.3%
Debt Repayment iN/AN/A
Common Stock Repurchase i-1,000-3.97B

Short Interest & Institutional Ownership Analysis

MetricRAPPREGN
Shares Short i3.85M2.55M
Short Ratio i10.604.46
Short % of Float i14.62%2.55%
Shares Outstanding i47.77M105.72M
Float Shares i30.79M98.55M
% Held by Insiders i4.56%1.98%
% Held by Institutions i106.74%91.08%
% Held by Public i-11.30%6.94%

Dividend Analysis & Yield Comparison: Rapport Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricRAPPREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026